ATE516348T1 - Glykoprotein vi und dessen anwendungen - Google Patents

Glykoprotein vi und dessen anwendungen

Info

Publication number
ATE516348T1
ATE516348T1 AT00946953T AT00946953T ATE516348T1 AT E516348 T1 ATE516348 T1 AT E516348T1 AT 00946953 T AT00946953 T AT 00946953T AT 00946953 T AT00946953 T AT 00946953T AT E516348 T1 ATE516348 T1 AT E516348T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecules
glycoprotein
expression vectors
provides isolated
Prior art date
Application number
AT00946953T
Other languages
English (en)
Inventor
Samantha Busfield
Jean-Luc Villelal
Martine Jandrot-Perrus
William Vainchencker
Davinder Gill
Ming Qian
Gillian Kingsbury
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27407686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516348(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/345,468 external-priority patent/US6245527B1/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE516348T1 publication Critical patent/ATE516348T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00946953T 1999-06-30 2000-06-30 Glykoprotein vi und dessen anwendungen ATE516348T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/345,468 US6245527B1 (en) 1999-06-30 1999-06-30 Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US45482499A 1999-12-06 1999-12-06
US09/503,387 US7291714B1 (en) 1999-06-30 2000-02-14 Glycoprotein VI and uses thereof
PCT/US2000/018152 WO2001000810A1 (en) 1999-06-30 2000-06-30 Glycoprotein vi and uses thereof

Publications (1)

Publication Number Publication Date
ATE516348T1 true ATE516348T1 (de) 2011-07-15

Family

ID=27407686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946953T ATE516348T1 (de) 1999-06-30 2000-06-30 Glykoprotein vi und dessen anwendungen

Country Status (5)

Country Link
US (5) US7291714B1 (de)
EP (3) EP1190043B1 (de)
AT (1) ATE516348T1 (de)
AU (1) AU6063500A (de)
WO (1) WO2001000810A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038675T2 (de) * 1999-05-07 2009-07-02 Sanofi-Aventis Deutschland Gmbh Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20090311267A1 (en) * 1999-08-10 2009-12-17 University Of Wurzburg Inhibition of VWF - GPIb/V/IX interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks
WO2001016321A1 (en) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (de) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
WO2003066661A2 (en) * 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
CA2453986A1 (en) 2001-07-18 2003-01-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Glycoprotein vi fusion proteins
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
EP1369128A1 (de) * 2002-06-07 2003-12-10 Procorde GmbH Glycoprotein VI Inhibitoren und deren therapeutische Verwendung
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1538165A1 (de) * 2003-12-03 2005-06-08 Procorde GmbH Glycoprotein VI Inhibitoren auf der Basis des monoklonalen Antikörpers hgp 5c4
CA2565063A1 (en) * 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Glycoprotein vi antibodies and method thereof
US7645592B2 (en) * 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2007030930A1 (en) 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
EP1916259A1 (de) 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung
US8278271B2 (en) * 2006-12-13 2012-10-02 University Of Massachusetts Inhibiting collagen-induced platelet aggregation and activation with peptide variants
US9410744B2 (en) 2010-05-12 2016-08-09 Molten Metal Equipment Innovations, Llc Vessel transfer insert and system
US20110044993A1 (en) * 2008-04-22 2011-02-24 Ulrich Kronthaler Method for the prevention and treatment of cancer by inhibition of gpvi
WO2010111240A2 (en) * 2009-03-23 2010-09-30 The Brigham And Women's Hospital, Inc. Methods for treating inflammatory arthritis
SG176644A1 (en) * 2009-06-03 2012-01-30 Regado Biosciences Inc Nucleic acid modulators of glycoprotein vi
US8889646B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8889645B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US9108244B2 (en) 2009-09-09 2015-08-18 Paul V. Cooper Immersion heater for molten metal
US8802826B2 (en) 2009-11-24 2014-08-12 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2336188A1 (de) * 2009-12-18 2011-06-22 Sanofi-Aventis Neuartige Antagonistenantikörper und ihre FAB-Fragmente gegen GPVI und Verwendungen davon
SG10201405259PA (en) 2009-12-18 2014-10-30 Sanofi Sa Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
EP2397495A1 (de) * 2010-06-21 2011-12-21 Sanofi Neuartige Antagonistenantikörper und ihre FAB-Fragmente gegen GPVI und Verwendungen davon
EP2402371A1 (de) * 2010-07-01 2012-01-04 Sanofi Neuartige Antagonistenantikörper und ihre FAB-Fragmente gegen GPVI und Verwendungen davon
CA2810479A1 (en) 2010-09-07 2012-03-15 Mochida Pharmaceutical Co., Ltd. Method for diagnosing alzheimer's disease using soluble gpvi in blood
US9029095B2 (en) 2010-12-01 2015-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method and kits for determining platelet susceptibility to activation in a patient
EP2817028A4 (de) 2012-02-22 2015-11-04 Alethia Biotherapeutics Inc Gemeinsame verwendung eines clusterin-inhibitors und eines egfr-inhibitors zur behandlung von krebs
EP4091628A1 (de) 2015-08-05 2022-11-23 Acticor Biotech Neuartige anti-human-gpvi-antikörper und verwendungen davon
TWI810173B (zh) 2017-02-03 2023-08-01 法商艾提寇生物技術公司 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
AU2019270342A1 (en) 2018-05-16 2020-10-29 Morphosys Ag Antibodies targeting glycoprotein VI
US20240182582A1 (en) * 2021-03-31 2024-06-06 Janssen Biothech, Inc. Materials and methods for immune effector cells redirection

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474893A (en) * 1892-05-17 Peanut-cleaner
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0247091B1 (de) 1985-11-01 1993-09-29 Xoma Corporation Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0264166B1 (de) 1986-04-09 1996-08-21 Genzyme Corporation Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
WO1991001140A1 (en) 1989-07-25 1991-02-07 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
US5874289A (en) * 1989-11-17 1999-02-23 Abbott Laboratories Bacillus thuringiensis mutants which produce high yields of crystal delta-endotoxin
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5198342A (en) * 1990-07-05 1993-03-30 Immunex Corporation DNA encoding IgA Fc receptors
EP0585287B1 (de) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8229291A (en) 1990-07-10 1992-02-04 Smithkline Beecham Corporation Oxamides
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0582595A1 (de) 1991-04-26 1994-02-16 Surface Active Limited Neue antikörper und verfahren zu ihrer verwendung
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE256738T1 (de) 1992-10-30 2004-01-15 Gen Hospital Corp Ein neues zellzyklus kontrollprotein
JPH08509857A (ja) 1993-01-07 1996-10-22 シーケノム・インコーポレーテッド マススペクトロメトリーによるｄｎａ配列決定法
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
EP0724599A1 (de) 1993-10-22 1996-08-07 Ellerman Pharmaceuticals Limited Analoga des plättchenherkommenden wachstumfaktors
EP0733070A1 (de) 1993-12-08 1996-09-25 Genzyme Corporation Herstellungsverfahen für spezifische Antikörper
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5763199A (en) 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2001509030A (ja) * 1997-01-21 2001-07-10 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｆｃレセプターおよびポリペプチド
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6448035B1 (en) * 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
WO1999011662A1 (en) 1997-09-05 1999-03-11 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
US6194151B1 (en) 1997-09-26 2001-02-27 Millenium Pharmaceuticals, Inc. Molecules of the TNF receptor superfamily and uses therefor
DE60038675T2 (de) 1999-05-07 2009-07-02 Sanofi-Aventis Deutschland Gmbh Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
CA2565063A1 (en) 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Glycoprotein vi antibodies and method thereof

Also Published As

Publication number Publication date
EP2322558B1 (de) 2015-01-07
US20100261200A1 (en) 2010-10-14
US20080050380A1 (en) 2008-02-28
EP1190043A4 (de) 2004-12-29
US7291714B1 (en) 2007-11-06
AU6063500A (en) 2001-01-31
EP2902414A1 (de) 2015-08-05
EP1190043A1 (de) 2002-03-27
US6989144B1 (en) 2006-01-24
EP1190043B1 (de) 2011-07-13
EP2322558A1 (de) 2011-05-18
WO2001000810A1 (en) 2001-01-04
US7597888B2 (en) 2009-10-06
US20060216291A1 (en) 2006-09-28
US8137923B2 (en) 2012-03-20

Similar Documents

Publication Publication Date Title
ATE516348T1 (de) Glykoprotein vi und dessen anwendungen
ATE353365T1 (de) Neue b7-4 moleküle und deren verwendungen
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
DE69837104D1 (de) An g-protein gekoppelte rezeptoren und deren verwendungen
DE69837268D1 (de) Neue moleküle aus der familie der tango-77-ähnlichen proteine und ihre verewendungen.
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
WO2002044354A3 (en) Molecules of the card-related protein family and uses thereof
DE60031418D1 (de) 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
EP1710299A3 (de) Sekretierte Proteine und dafür kodierende Polynukleotide
WO2000039149A3 (en) Secreted proteins and uses thereof
WO2001061005A3 (en) Molecules of the pyrin domain protein family and uses thereof
WO2002103015A3 (en) Abca10 transporter
DE60237613D1 (de) Neue pgc-1-isoformen und deren verwendungen
WO2001000673A8 (en) Membrane-associated and secreted proteins and uses thereof
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
ATE433489T1 (de) 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen
WO2000050442A3 (en) Secreted proteins and uses thereof
DE60125569D1 (de) 13245, eine neue, humane protein kinase vom typ myotonische dystrophie protein kinase und anwendungen davon
DE60136832D1 (de) Atcr-1, eine humane acyltransferase und verwendungen davon
WO2000039150A3 (en) Secreted proteins and uses thereof
ATE476194T1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
ATE445714T1 (de) 15603, ein mitglied der humanen ionenkanal- familie
DE60120974D1 (de) Proteinkinase-molekül 14911 und dessen anwendungen
WO2001074854A3 (en) 32449, a putative human transporter and uses thereof
DE60139153D1 (de) 14189, eine humane kinase und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties